{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:23:22Z","timestamp":1788819802970,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China Key Projects","award":["82230090"],"award-info":[{"award-number":["82230090"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Most cancers, including head and neck squamous cell carcinoma (HNSCC), frequently exhibit an approximately 80% lack of response to immune checkpoint blockade (ICB) therapy, largely attributed to hypoxia-induced tumor immune suppression. Although hypoxia is known to upregulate PD-L1 expression, the key mechanisms by which it enhances PD-L1 membrane localization and high expression remain elusive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We investigated the molecular mechanisms by which hypoxia enhances PD-L1 membrane localization in HNSCC cells. Additionally, we tested the efficacy of combining an anti-PD-1 antibody with the NMT1 inhibitor PCLX-001 in HNSCC xenograft mice and conducted a retrospective clinical study to assess NMT1 as a prognostic biomarker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our study revealed that hypoxia-inducible factor-1\u03b1 (HIF1\u03b1) upregulates N-myristoyltransferase 1 (NMT1), which mediates the myristoylation of calcineurin B homologous protein 1 (CHP1). Myristoylated CHP1 binds to PD-L1, facilitating its rapid translocation to the cell membrane and increasing PD-L1-mediated immune evasion. The NMT1 inhibitor low-dose PCLX-001 blocks CHP1 myristoylation, disrupting excessive PD-L1 membrane localization and attenuating cancer immune suppression. In HNSCC xenograft mice, administering an anti-PD-1 antibody combined with low-dose PCLX-001 via intratumoral injection significantly improved the treatment response rate and produced synergistic anticancer effects with no significant weight loss. Furthermore, our retrospective clinical study demonstrated that NMT1 protein levels can serve as an independent prognostic biomarker for HNSCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>These findings provide robust theoretical support for the translational application of combining NMT1 inhibitors and ICB therapy in cancers under hypoxic conditions. This study introduces a combined cancer therapy strategy named \"spatial blockade plus signaling inhibition of PD-L1.\"<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03438-z","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:12:06Z","timestamp":1751418726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy"],"prefix":"10.1186","volume":"44","author":[{"given":"Haoming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wantao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"3438_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.","journal-title":"Nat Rev Dis Primers"},{"key":"3438_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3438_CR3","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1002\/cncr.31675","volume":"124","author":"N Osazuwa-Peters","year":"2018","unstructured":"Osazuwa-Peters N, Simpson MC, Zhao L, Boakye EA, Olomukoro SI, Deshields T, Loux TM, Varvares MA, Schootman M. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer. 2018;124:4072\u20139.","journal-title":"Cancer"},{"key":"3438_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1397","volume":"11","author":"HS Rad","year":"2022","unstructured":"Rad HS, Shiravand Y, Radfar P, Ladwa R, Perry C, Han X, Warkiani ME, Adams MN, Hughes BG, O\u2019Byrne K, Kulasinghe A. Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clin Transl Immunology. 2022;11: e1397.","journal-title":"Clin Transl Immunology"},{"key":"3438_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"3438_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, Jr., Psyrri A, Baste N, Neupane P, Bratland A, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328.","journal-title":"Lancet"},{"key":"3438_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","volume":"7","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019;7:184.","journal-title":"J Immunother Cancer"},{"key":"3438_CR8","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.3390\/curroncol29060334","volume":"29","author":"JC Park","year":"2022","unstructured":"Park JC, Krishnakumar HN, Saladi SV. Current and Future Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. Curr Oncol. 2022;29:4185\u201398.","journal-title":"Curr Oncol"},{"key":"3438_CR9","volume":"33","author":"K Parmar","year":"2022","unstructured":"Parmar K, Mohamed A, Vaish E, Thawani R, Cetnar J, Thein KZ. Immunotherapy in head and neck squamous cell carcinoma: An updated review. Cancer Treat Res Commun. 2022;33: 100649.","journal-title":"Cancer Treat Res Commun"},{"key":"3438_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41467-019-14052-x","volume":"11","author":"Bhandari V, Li CH, Bristow RG, Boutros PC, Consortium P","year":"2020","unstructured":"Bhandari V, Li CH, Bristow RG, Boutros PC, Consortium P. Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 2020;11:737.","journal-title":"Nat Commun"},{"key":"3438_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/onc.2016.225","volume":"36","author":"S Chouaib","year":"2017","unstructured":"Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36:439\u201345.","journal-title":"Oncogene"},{"key":"3438_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al. The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia. J Hematol Oncol. 2021;14:92.","journal-title":"J Hematol Oncol"},{"key":"3438_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41467-024-54132-1","volume":"16","author":"HJ Hwang","year":"2025","unstructured":"Hwang HJ, Kang D, Shin J, Jung J, Ko S, Jung KH, Hong SS, Park JE, Oh MJ, An HJ, et al. Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation. Nat Commun. 2025;16:353.","journal-title":"Nat Commun"},{"key":"3438_CR14","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41594-024-01296-5","volume":"31","author":"RS Hegde","year":"2024","unstructured":"Hegde RS, Keenan RJ. A unifying model for membrane protein biogenesis. Nat Struct Mol Biol. 2024;31:1009\u201317.","journal-title":"Nat Struct Mol Biol"},{"key":"3438_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1152\/physrev.00032.2014","volume":"95","author":"LH Chamberlain","year":"2015","unstructured":"Chamberlain LH, Shipston MJ. The physiology of protein S-acylation. Physiol Rev. 2015;95:341\u201376.","journal-title":"Physiol Rev"},{"key":"3438_CR16","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Cancer Res. 2018;78:6349\u201353.","journal-title":"Cancer Res"},{"key":"3438_CR17","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","volume":"13","author":"C Shi","year":"2022","unstructured":"Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, Wang Y, Xie S, Shen Y, Sang L, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13:6951.","journal-title":"Nat Commun"},{"key":"3438_CR18","doi-asserted-by":"crossref","unstructured":"Li C, Chi H, Deng S, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J. THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. J Immunother Cancer. 2021;9(8):e002443.","DOI":"10.1136\/jitc-2021-002443"},{"key":"3438_CR19","doi-asserted-by":"crossref","unstructured":"Xu X, Xie T, Zhou M, Sun Y, Wang F, Tian Y, Chen Z, Xie Y, Wu R, Cen X, et al. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nat Commun. 2024;15(1):4237.","DOI":"10.1038\/s41467-024-48597-3"},{"key":"3438_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41422-018-0124-5","volume":"29","author":"Y Yang","year":"2019","unstructured":"Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, Hung MC. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019;29:83\u20136.","journal-title":"Cell Res"},{"key":"3438_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41401-020-0388-4","volume":"41","author":"M Yuan","year":"2020","unstructured":"Yuan M, Song ZH, Ying MD, Zhu H, He QJ, Yang B, Cao J. N-myristoylation: from cell biology to translational medicine. Acta Pharmacol Sin. 2020;41:1005\u201315.","journal-title":"Acta Pharmacol Sin"},{"key":"3438_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41423-021-00663-2","volume":"18","author":"B Wang","year":"2021","unstructured":"Wang B, Dai T, Sun W, Wei Y, Ren J, Zhang L, Zhang M, Zhou F. Protein N-myristoylation: functions and mechanisms in control of innate immunity. Cell Mol Immunol. 2021;18:878\u201388.","journal-title":"Cell Mol Immunol"},{"key":"3438_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-024-01759-7","volume":"9","author":"Y Yuan","year":"2024","unstructured":"Yuan Y, Li P, Li J, Zhao Q, Chang Y, He X. Protein lipidation in health and disease: molecular basis, physiological function and pathological implication. Signal Transduct Target Ther. 2024;9:60.","journal-title":"Signal Transduct Target Ther"},{"key":"3438_CR24","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging. CA Cancer J Clin. 2017;67:93\u201399.","journal-title":"CA Cancer J Clin"},{"key":"3438_CR25","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1038\/s41596-021-00601-6","volume":"16","author":"WW Kallemeijn","year":"2021","unstructured":"Kallemeijn WW, Lanyon-Hogg T, Panyain N, Goya Grocin A, Ciepla P, Morales-Sanfrutos J, Tate EW. Proteome-wide analysis of protein lipidation using chemical probes: in-gel fluorescence visualization, identification and quantification of N-myristoylation, N- and S-acylation, O-cholesterylation, S-farnesylation and S-geranylgeranylation. Nat Protoc. 2021;16:5083\u2013122.","journal-title":"Nat Protoc"},{"key":"3438_CR26","doi-asserted-by":"publisher","first-page":"11952","DOI":"10.1038\/s41598-020-68615-w","volume":"10","author":"YC Chen","year":"2020","unstructured":"Chen YC, Navarrete MS, Wang Y, McClintock NC, Sakurai R, Wang F, Chen KT, Chou TF, Rehan VK, Lee DJ, Diaz B. N-myristoyltransferase-1 is necessary for lysosomal degradation and mTORC1 activation in cancer cells. Sci Rep. 2020;10:11952.","journal-title":"Sci Rep"},{"key":"3438_CR27","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41467-020-14893-x","volume":"11","author":"T Kosciuk","year":"2020","unstructured":"Kosciuk T, Price IR, Zhang X, Zhu C, Johnson KN, Zhang S, Halaby SL, Komaniecki GP, Yang M, DeHart CJ, et al. NMT1 and NMT2 are lysine myristoyltransferases regulating the ARF6 GTPase cycle. Nat Commun. 2020;11:1067.","journal-title":"Nat Commun"},{"key":"3438_CR28","doi-asserted-by":"publisher","first-page":"1989790","DOI":"10.1080\/2162402X.2021.1989790","volume":"10","author":"KC Huang","year":"2021","unstructured":"Huang KC, Chiang SF, Ke TW, Chen TW, Hu CH, Yang PC, Chang HY, Liang JA, Chen WT, Chao KSC. DNMT1 constrains IFNbeta-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy. Oncoimmunology. 2021;10:1989790.","journal-title":"Oncoimmunology"},{"key":"3438_CR29","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JHC.S443130","volume":"11","author":"J Yan","year":"2024","unstructured":"Yan J, Li KX, Yu L, Yuan HY, Zhao ZM, Lin J, Wang CS. PRMT1 Integrates Immune Microenvironment and Fatty Acid Metabolism Response in Progression of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2024;11:15\u201327.","journal-title":"J Hepatocell Carcinoma"},{"key":"3438_CR30","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1080\/07853890.2023.2193425","volume":"55","author":"H Wang","year":"2023","unstructured":"Wang H, Xu X, Wang J, Qiao Y. The role of N-myristoyltransferase 1 in tumour development. Ann Med. 2023;55:1422\u201330.","journal-title":"Ann Med"},{"issue":"45\u201358","key":"3438_CR31","volume":"74","author":"XG Zhu","year":"2019","unstructured":"Zhu XG, Nicholson Puthenveedu S, Shen Y, La K, Ozlu C, Wang T, Klompstra D, Gultekin Y, Chi J, Fidelin J, et al. CHP1 Regulates Compartmentalized Glycerolipid Synthesis by Activating GPAT4. Mol Cell. 2019;74(45\u201358): e47.","journal-title":"Mol Cell"},{"key":"3438_CR32","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3:306\u201317.","journal-title":"Nat Biomed Eng"},{"key":"3438_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15:77.","journal-title":"J Hematol Oncol"},{"key":"3438_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12310","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Wu R, Zhai P, Liu Z, Xia R, Zhang Z, Qin X, Li C, Chen W, Li J, Zhang J. Hypoxia promotes EV secretion by impairing lysosomal homeostasis in HNSCC through negative regulation of ATP6V1A by HIF-1alpha. J Extracell Vesicles. 2023;12: e12310.","journal-title":"J Extracell Vesicles"},{"key":"3438_CR35","doi-asserted-by":"crossref","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132:e159839.","DOI":"10.1172\/JCI159839"},{"key":"3438_CR36","doi-asserted-by":"crossref","unstructured":"Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, Liu Y, Wang Y. Targeting HIF-1alpha abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Invest. 2022;132:e150846.","DOI":"10.1172\/JCI150846"},{"key":"3438_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"3438_CR38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/neuonc\/noae040","volume":"26","author":"S Yang","year":"2024","unstructured":"Yang S, Zhan Q, Su D, Cui X, Zhao J, Wang Q, Hong B, Ju J, Cheng C, Yang E, Kang C. HIF1alpha\/ATF3 partake in PGK1 K191\/K192 succinylation by modulating P4HA1\/succinate signaling in glioblastoma. Neuro Oncol. 2024;26:1405\u201320.","journal-title":"Neuro Oncol"},{"key":"3438_CR39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40164-023-00420-3","volume":"12","author":"Y Gu","year":"2023","unstructured":"Gu Y, Fang Y, Wu X, Xu T, Hu T, Xu Y, Ma P, Wang Q, Shu Y. The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications. Exp Hematol Oncol. 2023;12:58.","journal-title":"Exp Hematol Oncol"},{"key":"3438_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101\u20135.","journal-title":"Nature"},{"key":"3438_CR41","doi-asserted-by":"crossref","unstructured":"Zheng X, Mao H, Huo D, Wu W, Liu B, Jiang X. Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia. Nat Biomed Eng. 2017;1(4): 0057.","DOI":"10.1038\/s41551-017-0057"},{"key":"3438_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s44222-022-00004-6","volume":"1","author":"Y Chao","year":"2023","unstructured":"Chao Y, Liu Z. Biomaterials tools to modulate the tumour microenvironment in immunotherapy. Nature Reviews Bioengineering. 2023;1:125\u201338.","journal-title":"Nature Reviews Bioengineering"},{"key":"3438_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287\u2013305.","journal-title":"Nat Rev Clin Oncol"},{"key":"3438_CR44","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1038\/s41467-021-23496-z","volume":"12","author":"Y Dong","year":"2021","unstructured":"Dong Y, Gao Y, Ilie A, Kim D, Boucher A, Li B, Zhang XC, Orlowski J, Zhao Y. Structure and mechanism of the human NHE1-CHP1 complex. Nat Commun. 2021;12:3474.","journal-title":"Nat Commun"},{"key":"3438_CR45","doi-asserted-by":"publisher","first-page":"5348","DOI":"10.1038\/s41467-020-18998-1","volume":"11","author":"E Beauchamp","year":"2020","unstructured":"Beauchamp E, Yap MC, Iyer A, Perinpanayagam MA, Gamma JM, Vincent KM, Lakshmanan M, Raju A, Tergaonkar V, Tan SY, et al. Targeting N-myristoylation for therapy of B-cell lymphomas. Nat Commun. 2020;11:5348.","journal-title":"Nat Commun"},{"key":"3438_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni889","volume":"4","author":"EJ Wherry","year":"2003","unstructured":"Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4:225\u201334.","journal-title":"Nat Immunol"},{"key":"3438_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41590-018-0296-7","volume":"20","author":"Z Wen","year":"2019","unstructured":"Wen Z, Jin K, Shen Y, Yang Z, Li Y, Wu B, Tian L, Shoor S, Roche NE, Goronzy JJ, Weyand CM. N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. Nat Immunol. 2019;20:313\u201325.","journal-title":"Nat Immunol"},{"key":"3438_CR48","first-page":"9","volume":"2018","author":"JM Hsu","year":"1908","unstructured":"Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 1908;2018:9.","journal-title":"Nat Commun"},{"key":"3438_CR49","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41589-023-01392-5","volume":"19","author":"LT Henneberg","year":"2023","unstructured":"Henneberg LT, Singh J, Duda DM, Baek K, Yanishevski D, Murray PJ, Mann M, Sidhu SS, Schulman BA. Activity-based profiling of cullin-RING E3 networks by conformation-specific probes. Nat Chem Biol. 2023;19:1513\u201323.","journal-title":"Nat Chem Biol"},{"key":"3438_CR50","doi-asserted-by":"publisher","first-page":"12632","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"3438_CR51","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers. Nature. 2016;534:402\u20136.","journal-title":"Nature"},{"key":"3438_CR52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ni.2842","volume":"15","author":"J Arsenio","year":"2014","unstructured":"Arsenio J, Kakaradov B, Metz PJ, Kim SH, Yeo GW, Chang JT. Early specification of CD8+ T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. Nat Immunol. 2014;15:365\u201372.","journal-title":"Nat Immunol"},{"key":"3438_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/ni.3031","volume":"15","author":"JT Chang","year":"2014","unstructured":"Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014;15:1104\u201315.","journal-title":"Nat Immunol"},{"key":"3438_CR54","doi-asserted-by":"crossref","unstructured":"Ma J, Chen T, Wu S, Yang C, Bai M, Shu K, Li K, Zhang G, Jin Z, He F, et al: iProX: an integrated proteome resource. Nucleic Acids Res. 2019;47:D1211-7.","DOI":"10.1093\/nar\/gky869"},{"key":"3438_CR55","doi-asserted-by":"crossref","unstructured":"Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y, Fu Y, Yang C, Li M, Wu S, et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2022;50:D1522-7.","DOI":"10.1093\/nar\/gkab1081"}],"updated-by":[{"DOI":"10.1186\/s13046-025-03533-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03438-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03438-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T07:03:15Z","timestamp":1756969395000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03438-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3438"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03438-z","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13046-025-03533-1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors identified few minor errors in the published version of their article","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-025-03533-1","URL":"https:\/\/doi.org\/10.1186\/s13046-025-03533-1","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University. All the mice were housed in a specific pathogen-free (SPF) facility and euthanized with carbon dioxide. All animal experiments were conducted in strict accordance with protocols approved by the Ethics Committee of the Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University. The tumor size allowed in the experiment did not exceed 2000 mm3, and we adhered to this limit to ensure that the animals did not suffer undue harm and that the experimental results were valid and reproducible.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to the content of the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}